The companies will work with investigators to share the results with the scientific community
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The company is already marketing the 4 mg and 10 mg strengths
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
The product will be manufactured at Lupin's facility in Goa, India.
Subscribe To Our Newsletter & Stay Updated
